Tumor-associated macrophages have recently emerged as a key regulatory cell type during cancer progression, and have been found to promote tumor malignancy in the majority of studies performed to date. We show in this study that CD68
Introduction
Pancreatic neuroendocrine tumors (PNETs) are a relatively rare type of cancer when compared with pancreatic ductal adenocarcinoma (o5% of total pancreatic cancer cases) (Halfdanarson et al., 2008) .
It is believed that at least a subset of PNETs develop from endocrine cells of the islets of Langerhans. More than 50% of PNETs will present with metastasis, and conventional chemotherapy lacks efficacy in this tumor type. As a result, there is a large variance in outcome and limited pathological prognostic information is available for these patients (Halfdanarson et al., 2008; Reidy et al., 2009) , emphasizing the importance of gaining an improved understanding of the pathological mechanisms driving disease progression.
The non-cancerous stromal cells within the microenvironment are known to contribute to tumor development and can also influence therapeutic response (Joyce and Pollard, 2009 ). Infiltrating macrophages generally account for the largest immune cell population within tumors and accumulating evidence points to their critical involvement in malignancy (Bingle et al., 2002; Qian and Pollard, 2010) . Tumor-associated macrophages (TAMs) have been clinically linked to poor prognosis and malignant progression in numerous types of cancers, including breast cancer, thyroid cancer and Hodgkin's lymphoma, among others (Lewis and Pollard, 2006; Ryder et al., 2008; Robinson et al., 2009; Steidl et al., 2010) . Although such studies using patient samples have been very informative, they are largely correlative, and thus our current knowledge of the functional roles of macrophages within the tumor microenvironment derives in large part from mouse models of cancer.
Macrophage differentiation, proliferation and survival are dependent on the growth factor colony-stimulating factor-1 (CSF-1), which signals through its receptor CSF-1R. Csf1 op/op mice harbor a naturally occurring thymidine insertion mutation that results in a frameshift and creation of a premature stop codon, and thus blocks any functional protein production (Wiktor-Jedrzejczak et al., 1990; Yoshida et al., 1990) . As a result, these CSF-1 null mice are deficient for most tissue resident macrophage populations (Chitu and Stanley, 2006) . Breeding the Csf1 op/op mouse to the transgenic MMTVPyMT model of breast cancer significantly impaired tumor angiogenesis and metastasis to the lung, while primary tumor growth and proliferation were unaffected (Lin et al., 2001 (Lin et al., , 2006 . In Csf1 op/op ; Apc D716 mice, intestinal tumorigenesis was significantly reduced, with the most striking decrease in the number of large polyps (Oguma et al., 2008) . Alternative strategies for targeting TAMs have similarly revealed pro-tumorigenic roles for these cells, but the mechanisms varied depending on the cancer model and tissue context (Qian and Pollard, 2010) . With a burgeoning interest in therapeutically targeting the CSF-1/CSF-1R signaling pathway, these studies highlight the necessity to better understand the distinct functions of TAMs within different tumor microenvironments.
RIP1-Tag2 (RT2) transgenic mice model pancreatic neuroendocrine tumorigenesis. In this model, the p53 pathway is suppressed by SV40-T-antigen in the pancreatic islet cells (Hanahan 1985) , and p53 function is attenuated in approximately 70% of human PNETs (Hu et al., 2010) . Importantly, the RT2 model has been shown to have predictive value in preclinical studies. For example, both mTOR and VEGFR inhibitors exhibited potent antitumor efficacy in the RT2 model (Pietras and Hanahan, 2005; Chiu et al., 2010) , and have recently been shown to significantly improve progression-free survival of patients in phase III clinical trials (Raymond et al., 2011; Tuveson and Hanahan, 2011; Yao et al., 2011) . We have previously shown that cysteine cathepsin proteases supplied by TAMs are critical for RT2 tumor growth, invasion and angiogenesis (Gocheva et al., 2010b) , and therefore we sought to more closely examine the role of macrophages in PNET progression.
In the present study, we found there is a significant positive correlation between macrophage infiltration and adverse pathological and clinical features in human PNETs. We next sought to investigate the role of CSF-1-dependent macrophages by breeding the Csf1 op/op mouse to the RT2 model of pancreatic islet tumor progression. Herein we demonstrate that absence of the macrophage growth factor CSF-1 significantly reduces tumor burden in RT2 mice, which interestingly resulted from a decrease in angiogenic switching and subsequent tumor formation.
Results and discussion

Investigation of TAMs in human PNETs
PNETs are rare diseases, but pose major clinical challenges that arise in part from marked disease heterogeneity and varied patient outcome (Halfdanarson et al., 2008) . One of the clinical challenges is to accurately stratify patients into prognostic groups that could provide critical benefits in clinical management of the disease. Tumor-infiltrating macrophages have been linked to invasion and metastasis in many types of cancers; however, the significance of macrophages in PNETs has not been investigated. Thus we sought to determine if macrophage infiltration is similarly correlated with tumor aggressiveness in PNETs. Tumors were immunohistochemically stained for CD68 and scored blindly as follows: low (1), medium (2) and high (3) macrophage infiltration (Figure 1a ). Samples were decoded, revealing a significant correlation between increased macrophage levels and higher tumor grade and stage (World Health Organization classification), and proliferative activity (Figures 1b-d (Figure 2a ). The purity of the sorted populations was confirmed by the expression of the initiating oncogene, SV40 T-antigen, only in the tumor cell fraction and Cd68 solely in the macrophages. Although the ligand Csf1 was expressed by both tumor cells and macrophages, Csf1r was only expressed by macrophages. These findings were confirmed by immunostaining, showing that all CSF-1R þ cells co-stained for the macrophage cell-type-specific marker CD68 in both wild-type (WT) and Csf1 op/op RT2 mice, in which there were fewer tumor-infiltrating macrophages (Figure 2b ). This allows us to conclude that any alteration in the tumorigenic phenotypes of the Csf1 op/op RT2 mice are macrophage dependent.
We next assessed the effects of CSF-1 deficiency on pancreatic neuroendocrine tumorigenesis by examining cohorts of Csf1 op/op and WT RT2 mice at 13.5 weeks, and the number of tumors, individual and cumulative tumor volumes were calculated for each genotype. The number of pancreatic islet tumors was significantly reduced by 62% in Csf1 op/op RT2 mice (2.77±0.45 per mouse) compared with WT RT2 littermates (7.38±0.74) (Figure 3a , Po0.0001). Correspondingly, the cumulative tumor burden was also significantly decreased by 56% in Csf1 op/op RT2 animals (21.10±9.33) compared with WT (48.37 ± 17.84) (Figure 3b , Po0.005). Although the total tumor volume, comprising all tumors in each animal, was reduced in the Csf1 op/op mice, when we analyzed the distribution of individual tumor volumes there was no difference between the genotypes (Figure 3c ). This suggests that the reduced cumulative tumor burden was predominantly a consequence of a significant decrease in tumor number, rather than an effect on subsequent tumor growth.
Tumor development in the RT2 model progresses through sequential stages including pre-neoplastic hyperplastic islets and angiogenic islets, as well as various grades of carcinoma (Hanahan 1985) . To determine if the decrease in tumor number stems from an effect at an earlier pre-neoplastic stage, we analyzed angiogenic switching at 10.5 weeks. We compared the number of angiogenic islets in the Csf1 op/op RT2 mice and their WT RT2 littermates, and found there was a 35% decrease ( Figure 3d , Po0.05).
Thus, it appears that the pronounced reduction we observed in tumor multiplicity in Csf1 op/op RT2 mice at 13.5 weeks arises in part from an earlier defect in the frequency of angiogenic switching at 10.5 weeks, which is a rate-limiting step in this model that determines the subsequent ability of tumors to form. Although it has previously been shown that there is a decrease in normal islet cell proliferation in Csf1 op/op mice during fetal development, this effect was normalized when mice were analyzed at later stages; at weaning and in adults there were no significant differences (Banaei-Bouchareb et al., 2004) . Therefore, we conclude that the pronounced 62% reduction in tumor number in Csf1 op/op RT2 mice results in part from a 35% decrease in angiogenic switching, and perhaps an impairment in the transition from angiogenic islets to end-stage tumors that may require continued CSF-1. sections from primary PNETs (n ¼ 27) were immunohistochemically stained for macrophages with a pre-diluted monoclonal mouse anti-human CD68 antibody (clone PG-M1, Dako, Carpinteria, CA, USA) and DAB detection using a Discovery XT automated staining processor (Ventana Medical Systems, Inc., Tuscon, AZ, USA). Stained tissue sections were then blindly scored by two independent investigators for the CD68 þ macrophage density and classified into low (CD68 score 1), medium (CD68 score 2) or high (CD68 score 3). Representative images are depicted in (a). Scale bar, 50 mm. (b-e) CD68 scores for each tumor were then de-coded and matched with their corresponding clinicopathological data: (b) for histological tumor grade (low n ¼ 17, intermediate n ¼ 8, high ¼ 2; Po0.01 by Fisher's exact test); (c) World Health Organization tumor stage (1.1 n ¼ 4, 1.2 n ¼ 12, 2.0 n ¼ 11; Po0.001 by Fisher's exact test); (d) the number of mitoses per 50 high-powered fields (Po0.05 by one way analysis of variance); (e) the absence and presence of distant metastasis (No-Met n ¼ 20, Liver-Met n ¼ 7; Po0.005 by Fisher's exact test). Statistical analyses were performed using SPSS Statistics version 19 (IBM, Armonk, NY, USA). Further information for these clinicopathological parameters tested in association with CD68 levels are in Supplementary Table 2. mice, we next sought to determine how specific hallmark capabilities of cancer, namely cell proliferation, apoptosis, tumor angiogenesis and invasion (Hanahan and Weinberg, 2000) were affected in the Csf1 op/op RT2 mice. Tumors from Csf1 op/op RT2 and WT RT2 mice at 13.5 weeks were first analyzed for cell proliferation by assessing BrdU incorporation. This analysis revealed no significant difference in cell proliferation in Csf1 op/op RT2 tumors (Supplementary Figure 1a) . We subsequently quantified apoptosis in tumors from Csf1 op/op RT2 and WT RT2 mice using cleaved caspase 3 staining, and also found no significant difference (Supplementary Figure 1b) . These results are consistent with our observations that the reduction in cumulative tumor burden in Csf1 op/op RT2 mice results from a decrease in tumor number (Figure 3a) , rather than any obvious effect on subsequent tumor growth.
Analysis of hallmark capabilities of cancer in CSF-1-deficient tumors
Macrophage depletion has been shown to impair tumor angiogenesis in other contexts, such as in Csf1 op/op ; PyMT mammary tumors (Lin et al., 2006) , and so we were interested to determine how neoplastic angiogenesis might be affected in RT2 tumors. We first examined immunoreactivity of the vascular marker CD31 in Csf1 op/op RT2 tumors compared with WT RT2 tumors, and surprisingly found no significant difference (Supplementary Figures 1c  and d) . Similarly, pericyte coverage of blood vessels was also unaffected in Csf1 op/op RT2 lesions (Supplementary Figure 1e) . Finally, we examined tumor invasion in both genotypes by grading lesions at 13.5 weeks into encapsulated tumors, microinvasive carcinomas and invasive carcinomas, as previously described (Lopez and Hanahan, 2002) . Csf1 op/op mice showed no change in the spectrum of tumor grades compared with WT RT2 mice (Supplementary Figure 1f) . 
þ , green bars). After sorting, the cells were spun down and the pellet resuspended in Trizol for RNA isolation. RNA was DNase treated, amplified using the MEGAscript T7 kit (Applied Biosystems, Carlsbad, CA, USA), and 1 mg of amplified RNA was used for complementary DNA synthesis. Taqman probes (Applied Biosystems) for SV40 T-Antigen (T-Ag; custom probe, Applied Biosystems), Cd68 (Mm00839636_g1), Csf1 (Mm00432688_m1) and Csf1r (Mm00432689_m1) were used for q-PCR. Assays were run in triplicate and expression was normalized to ubiquitin C (Mm01201237_m1) for each sample. Data are represented as mean ± standard error of measurement of three independent sorts. (b) Double immunostaining of frozen sections from 13.5-week old WT RT2 (top panel) and Csf1 op/op RT2 pancreas (bottom panel) for CSF-1R (red; rabbit polyclonal anti-human c-Fms/CSF-1R, clone C-20, 1:200, Santa Cruz, Santa Cruz, CA, USA) and macrophages (green; rat monoclonal anti-mouse CD68, clone FA-11, 1:1000, Serotec). Cell nuclei are visualized with DAPI (blue). T, tumor; E, exocrine pancreas (normal tissue). Scale bar, 50 mm.
Collectively, these analyses demonstrated that there were no significant differences in these specific hallmark capabilities of cancer in end-stage tumors from Csf1 op/op RT2 mice. This was somewhat surprising, as there are clear differences in cumulative tumor burden, as a consequence of reduced angiogenic switching and tumor number (Figure 3) , and suggests that the end-stage tumors which do form in the Csf1 op/op mice are not impaired in any of these processes. This result was also unanticipated given the critical role for macrophagesupplied cathepsin proteases in RT2 tumor growth, angiogenesis and invasion (Gocheva et al., 2010b) , and thus we sought to investigate the levels of macrophage depletion more fully.
Myeloid infiltration of RT2 tumors is altered in the absence of CSF-1
To examine the effects on macrophage infiltration into RT2 lesions at each stage of pre-neoplastic and neoplastic progression, Csf1 op/op RT2 and WT RT2 pancreatic tissues were stained with CD68. The number of macrophages in the normal exocrine pancreas, normal islets, hyperplastic islets, angiogenic islets and tumors was quantified using TissueQuest analysis software (TissueGnostics, Vienna, Austria) as previously described (Steiner et al., 2000; Gocheva et al., 2010a) . Although macrophages were significantly depleted at all stages of RT2 tumorigenesis, neoplastic lesions had higher levels of persistent macrophages compared with normal pancreatic tissues within the same mouse. The normal islets and exocrine pancreas exhibited an 83-84% reduction in macrophages, yet the number of infiltrating macrophages at each successive stage (hyperplastic, angiogenic islets and tumors) was decreased by only 46-54% (Figures 4a and b) . These results were confirmed by staining with an independent macrophage-specific marker, Iba1, which has generally been used to stain brain-resident macrophages known as microglia, but has also been shown to label other tissue macrophage populations (Ko¨hler, 2007) . We first showed that Iba1 labels the vast majority of F4/80-positive macrophages in RT2 tumors (Supplementary Figure 2a) , 
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P < 0.05 P < 0.005 P < 0.0001 ns Figure 3 Tumor development is impaired in Csf1 op/op RT2 mice. The generation of RIP1-Tag2 (RT2) mice has been previously reported (Hanahan 1985) . Heterozygous Csf1 op/ þ mice in the C57BL/6 background were purchased from Jackson Laboratories. The Csf1 op/ þ and RT2 mice were intercrossed to generate homozygous Csf1 op/op mutants with the RT2 transgene, which could also be phenotypically identified by their lack of incisors and domed skull. Littermate Csf1 op/ þ and Csf1 þ / þ , henceforth denoted as wild type (WT), mice were genotyped by PCR and restriction enzyme digestion as previously described (Abboud et al., 2002) , or by PCR followed by pyrosequencing (protocol courtesy of Dr. Jeffrey Pollard, Albert Einstein College of Medicine). All animal studies were approved by the Institutional Animal Care and Use Committee of Memorial Sloan-Kettering Cancer Center. (a-c) To assess pancreatic islet tumorigenesis, WT RT2 (black dots, n ¼ 21) and Csf1 op/op RT2 mice (gray dots, n ¼ 22) were euthanized at 13.5 weeks of age. The total number of tumors per mouse (a) and the cumulative tumor volume (sum total of the individual tumor volumes per mouse) (b) were determined as previously described (Gocheva et al., 2010a) . Each dot represents an individual mouse, and the horizontal line the mean. Tumor number, Po0.0001 by unpaired Student's t-test. Because of the large, variable distribution of the cumulative tumor volumes, statistical analysis was performed with the non-parametric Mann-Whitney test, Po0.005. (c) To determine if there was a shift in the distribution of tumor size, individual tumors were classified by volume and represented as a proportion of the total number of tumors. Tumor sizes were compared between genotypes using a linear regression model with generalized estimating equations to correct for correlations within mice (ns, not significant). (d) Angiogenic switching was analyzed in WT RT2 (n ¼ 28) and Csf1 op/op RT2 (n ¼ 7) mice by counting the number of angiogenic islets per mouse at 10.5 weeks of age. Each dot represents an individual mouse, and the line the mean, Po0.05 by unpaired Student's t-test.
and then assessed Iba1
þ cell numbers in Csf1 op/op RT2 tumors, which revealed similar reductions in macrophage infiltration (Supplementary Figures 2b and c) .
As we have previously shown that macrophagesupplied cathepsin proteases are important modulators of tumor growth and invasion (Gocheva et al., 2010b) we wanted to investigate whether the levels of cathepsin activity were altered in the Csf1 op/op RT2 tumors. We injected mice with a Cy3B-conjugated cathepsin activity-based probe as previously described (Gocheva et al., 2010b) , and found that the TAMs that are capable of infiltrating RT2 tumors in the absence of CSF-1 still exhibit high levels of cathepsin activity, as in WT tumors (Figure 4c) .
Because macrophage depletion in other contexts has led to a corresponding increase in neutrophils, we also stained Csf1 op/op tumors for neutrophils using a 7/4 antibody. We found that neutrophil infiltration was significantly increased by 2.9-fold (Figures 4d and e,  Po0.05 ). This result mirrors a similar finding by Hanahan and colleagues in the K14-HPV/E 2 mouse model of cervical cancer (Pahler et al., 2008) . In this transgenic model, when macrophages were depleted following genetic deletion of the chemokine receptor CCR2, there was a resulting increase in the infiltration of neutrophils. The authors proposed that this was the consequence of a compensatory response to macrophage depletion, which may also be the case in our model system. Interestingly, neutrophils have been implicated in the regulation of angiogenic switching in the RT2 model, based on a reduction in the number of angiogenic islets following an anti-Gr-1 antibody depletion strategy (Nozawa et al., 2006) .
Our data indicate that there are CSF-1-independent mechanisms for macrophage recruitment in RT2 tumors, as TAMs are clearly still present in Csf1 op/op RT2 lesions, albeit at reduced levels. We also observe a significant increase in neutrophil recruitment. To investigate whether Csf1 op/op tumors evoke compensatory mechanisms to recruit myeloid cells, we examined the mRNA expression levels of a panel of growth factors, cytokines and chemokines known to be involved in macrophage proliferation, differentiation and/or the recruitment of myeloid cells (Hamilton 2008; Lin et al., 2008; Mantovani et al., 2010) .
A factor of interest was the recently identified CSF-1R ligand interleukin-34, which can mediate macrophage proliferation and differentiation, is known to be expressed in the pancreas, and can rescue many of the phenotypes of Csf1 op/op mice when transgenically expressed under the control of the Csf1 promoter (Lin et al., 2008; Wei et al., 2010) . We found no compensatory upregulation of interleukin-34 in Csf1 op/op RT2 tumors (Figure 4f) , which is consistent with the findings of Wei et al. (2010) who also failed to observe an increase in the mRNA expression of interleukin-34 in several tissues of Csf1 op/op mice. To determine if other myeloid colony-stimulating factors are expressed in RT2 tumors, we included G-CSF and GM-CSF in our analysis; while G-CSF expression was elevated in one WT and one Csf1 op/op RT2 tumor (Figure 4f ), GM-CSF failed to amplify in any of the tumors tested. Pollard and colleagues have observed that overexpression of the angiogenic factor VEGF-A induces a large influx of macrophages in MMTV-PyMT tumors (Lin et al., 2007) . Because VEGF-A is known to be highly expressed in pancreatic islets and is modestly upregulated during RT2 tumorigenesis (Christofori et al., 1995) , we analyzed its expression in Csf1 op/op RT2 tumors. Although VEGF-A was not increased in þ macrophages relative to the total number of 46-diamidino-2-phenyl indole (DAPI) þ cells was quantitated with TissueQuest Analysis software (TissueGnostics) as previously described (Steiner et al., 2000; Gocheva et al., 2010a) . For all islets and neoplastic lesions, macrophages in the surrounding normal exocrine pancreas were excluded from the analysis; regions of interest were selected as in (a). Graph depicts the mean percentage of macrophages per mouse for each stage ± standard error of measurement (SEM) (n ¼ 5 mice per genotype). Statistical analysis by unpaired Student's t-test was performed both between genotypes matched for stage, and within the same genotype between stages of increasing malignancy, for example, hyperplastic versus angiogenic, angiogenic versus tumor, and so on; *Po0.05, **Po0.005, ***Po0.001. (c) RT2 mice were intravenously injected with 100 ml of 1 mM Cy3B-labeled cathepsin activity-based probe (Cath-ABP), which was allowed to circulate for 1 h before euthanizing the animals, as previously described (Greenbaum et al., 2002; Gocheva et al., 2010b) . Pancreatic tissue from Cath-ABP-injected mice was stained for CD68 as in (a). 3. We found that while no single factor was consistently upregulated in all cases, and no single tumor had a global increase in all genes examined, some cytokines exhibited higher levels of expression in several Csf1 op/op RT2 tumors. This suggests the possibility that neoplastic lesions may be able to recruit myeloid cells through heterogeneous compensatory mechanisms. Additionally, sufficient numbers of TAMs may be recruited via CSF-1-independent molecular mechanisms that operate both in WT and Csf1 op/op tumors. Taken together, these data suggest that CSF-1-dependent macrophages are critical in the rate-limiting step during the transition from a pre-neoplastic islet to tumor in the RT2 model; those lesions which are able to overcome this step and develop subsequently have sufficient TAMs such that there is no further hindrance in promoting the hallmark capabilities of cancer (Supplementary Figure 1) . Our study thus highlights the differential response in targeting a specific cell type within the microenvironment versus targeting their downstream effector mechanisms (Gocheva et al., 2010b) . It also underscores the plasticity of macrophage populations as, in the absence of CSF-1, pancreatic TAMs are still able to persist; this may occur potentially via alternative activation of CSF-1R through interleukin-34, or by CSF-1R-independent signaling pathways. Also, the observed increase in neutrophils suggests that a disturbance in one myeloid compartment may allow for a corresponding increase in another. This finding is not specific to our study, as the treatment of mice with a CSF-1R-blocking antibody increases the recruitment of granulocytes in two different inflammatory contexts (Macdonald et al., 2010) , and, as discussed above, CCR2 knockout mice have increased neutrophil infiltration in a model of cervical carcinogenesis (Pahler et al., 2008) .
This reinforces the importance of determining the specific roles of CSF-1-dependent TAMs in different tissue contexts, as the macrophage depletion is much more striking in Csf1 op/op mouse models of breast cancer and intestinal tumorigenesis (Lin et al., 2001; Oguma et al., 2008) . Moreover, in these two models, the effects of CSF-1 removal were evident in the reduction of metastasis and the growth of large tumors respectively, whereas our findings in this study in the RT2 model implicate CSF1-dependent macrophages in promoting angiogenic switching and subsequent tumor development.
Importantly, we have confirmed herein the critical role of macrophages from mouse models to human tumors, and identified the correlation between TAM infiltration and clinical aggressiveness of PNETs. In summary, our investigation further establishes a pivotal role for macrophages in cancer development and progression.
